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http:WHAT THIS PAPER ADDS
The present study investigated quality of life (QoL) at a median of 35 months follow up after bone marrow
derived cell therapy for severe limb ischemia. QoL is becoming a more important outcome measure, as
amputation rates drop globally. Studies investigating cell therapy in limb ischemia do not usually have long-term
follow up results. In the present study, QoL is still increased after almost 3 years, both in the cell treated and
placebo arms. The information in the current manuscript is valuable for future trials, since it shows that QoL
improvement persists even after long-term follow up, in both the treatment and placebo groups. This also
underlines the importance of placebo controlled studies in (cell therapy) trials in limb ischemia.Objective: Quality of life (QoL) is an important outcome in evaluating treatment effect in severe limb ischemia.
The randomized, double blind, placebo controlled JUVENTAS trial, investigating the effect of bone marrow
derived mononuclear cell (BMMNC) administration in no option severe limb ischemia, showed an improved QoL
at 6 months compared with baseline in both the treatment and placebo groups. The aim of the present study was
to evaluate whether the improved QoL persisted beyond 6 months’ follow up, whether this differed in both trial
arms, and if major amputation inﬂuenced QoL.
Methods: Short form 36 (SF-36) and EuroQol 5D (EQ5D), including the EQ Visual Analogue Scale (EQ-VAS),
questionnaires were sent to JUVENTAS trial participants. In the JUVENTAS trial, a norm based scoring method
was applied to report the results of the SF-36. The results of the long-term follow up were compared with
baseline and 6 month follow up and the results of both trial arms were compared, as were the results of patients
with and without amputation.
Results: One hundred and nine patients (86.5% of surviving patients) responded to the questionnaires. Median
follow up after inclusion was 33 months (interquartile range [IQR] 21.2e50.6) for the BMMNC and 36 months
(IQR 21.4e50.9) for the placebo group. The improvement in QoL at 6 months persisted in both arms at a median
follow up of 35 months. The long-term QoL did not differ between the BMMNC and placebo group in any of the
SF-36 or EQ5D domains. Patients with and without a major amputation had similar QoL scores.
Conclusions: The increased QoL in patients with no option severe limb ischemia persisted until 3 years after
inclusion, but did not differ between the BMMNC and placebo arms or between patients with and without a
major amputation.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2015.09.010prognosis for both life and limb, low quality of life (QoL),
and high treatment costs.1,2 A considerable proportion
of these patients will reach a stage where revascularization
is not an option, and effective pharmacological therapies for
severe limb ischemia are lacking. Hence, major amputation
is often inevitable.3 Therefore, novel treatment options are
needed, and regenerative medicine strategies, for instance
cell based therapies seem promising.4
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QoL is increasingly appreciated as an important outcome
to evaluate treatment success in severe limb ischemia,
and improving QoL has become an important treatment
goal in this patient population.3,5 Several validated in-
struments are available to assess health related QoL. One
of these is the Medical Outcomes Study Short Form 36
(SF-36) Health Survey, a QoL questionnaire that is widely
accepted, validated, and commonly used for the assess-
ment of QoL in various diseases, such as peripheral arte-
rial disease (PAD).6 Patients with no option severe limb
ischemia, participating in the JUVENTAS (reJUVenating
ENdothelial progenitor cells via Transcutaneous intra-
Arterial Supplementation) trial had worse outcomes in
almost every domain of the SF-36 questionnaire than
patients with less severe PAD and patients with cardio-
vascular risk factors only.1 The results of the JUVENTAS
trial showed relatively low amputation and mortality rates
in both the bone marrow derived mononuclear cell
(BMMNC) and placebo groups, with no signiﬁcant differ-
ences between the groups.7 The study also reported
improved QoL after 6 months compared with baseline in
both the BMMNC and the placebo group, without signif-
icant differences between the groups. Since there was an
improvement in QoL in both groups, the question of
whether this may be a result of trial participation itself
was raised. The authors have investigated whether this
increase in QoL compared with baseline persists in theFigure 1. Patient recruitment and trial ﬂow showing the patient ﬂo
ABI ¼ indicates ankle brachial index; BMMNC ¼ bone marrow mononlong-term after ﬁnishing the study, when the extra
attention and care would be ended. In addition it was
assessed whether long-term QoL was inﬂuenced by major
amputation.METHODS
The JUVENTAS study was a randomized, placebo controlled,
double blind clinical trial that aimed to investigate whether
repeated intra-arterial infusion of BMMNCs reduces major
amputation rates compared with placebo in a large cohort
of no option severe limb ischemia patients. Patients were
included from September 2006 through June 2012 if they
had severely limiting intermittent claudication or limb
ischemia and were not suitable for surgical or endovascular
revascularization. A ﬂow chart of the study design is dis-
played in Fig. 1.
The study rationale and design have been published
previously.8 QoL was assessed at inclusion and 2 and 6
months follow up in the JUVENTAS trial. The study showed
no differences in amputation and mortality rates between
the BMMNC and placebo group of the trial, and QoL, rest
pain, ankle brachial index (ABI), and transcutaneous oxygen
(tcO2) pressure improved in both the BMMNC and placebo
group, without differences between them.7 The main ﬁnd-
ings of the trial are summarized in Box 1.
Validated Dutch versions of the short form 369 and
EuroQol 5D-3 level version10 (EQ5D-3L) questionnaires werew during the initial JUVENTAS study and long-term follow up.
uclear cell.
Box 1. Summary of JUVENTAS trial results.
 At 6 months’ follow up, no signiﬁcant differences were
observed for the primary outcome, i.e. major
amputation (19% in BMMNC group vs. 13% in placebo
group).
 The safety outcome (all cause mortality, occurrence of
malignancy, or hospitalization due to infection) was not
signiﬁcantly different between the groups (relative risk
1.46, 95% conﬁdence interval 0.63e3.38).
 Secondary outcomes (quality of life, rest pain, ankle
brachial index, and transcutaneous oxygen pressure)
improved during follow up, without signiﬁcant
differences between the groups.
 SF-36 physical component summary increased with 6.3
points (IQR 4.1e8.4) in BMMNC group and 6.4 points
(IQR 3.9e8.8) in placebo group. Mental component
summary increased with 3.9 points (0.0e7.8) in BMMNC
group and 1.7 points (IQR 2.6e5.9) in placebo group.
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long-term QoL, the same QoL questionnaires as used during
the study were sent to all patients who were still alive 9
months after the last participant completed the 6 month
follow up of the trial. At the time of questionnaire
completion, patients were still blinded to the assigned
treatment. Patients were requested to complete and return
the forms; after 2 months a reminder was sent to the non-
responding participants.
Major amputation was deﬁned as amputation through or
above the ankle. For the analyses, a difference was made
between patients who suffered a major amputation since
randomization and patients who suffered any major
amputation before or after randomization.
This study was conducted according to the declaration of
Helsinki and approved by the institutional review board.QoL questionnaires
The scores of the eight health dimensions of the SF-36 were
calculated, with the norm based scores (NBS) and the
physical (PCS) and mental component summary (MCS)
scores, as explained previously.1
The EQ5D-3L consists of ﬁve domains, which were com-
bined in one score (the mean tariff score), and the self rated
EQ-VAS score. The methods for calculating these scores
were also reported previously.1Data analysis
Data were analyzed using SPSS for Windows version 22
(SPSS Inc., Chicago, IL, USA). Statistical signiﬁcance was
considered at a double sided p < .05, with a Bonferroni
correction to adjust for multiple testing. Missing items were
imputed if at least 50% of the items had been completed for
that speciﬁc health dimension; if patients did not return the
questionnaire they were omitted from the analyses. Missing
data were imputed using the “multiple imputation” func-
tion in SPSS. KolmogoroveSmirnov tests for normality wereperformed and data with a normal distribution were
analyzed using the Student t test, and expressed as
mean  SD, while non-normally distributed data were
analyzed using the ManneWhitney U or Wilcoxon rank test,
and expressed as medians with interquartile range (IQR).
Possible predictors for QoL were previously determined
based on clinical relevance and analyzed using a linear
regression model. For this regression model, the age of
patients was divided into 10 year categories.
RESULTS
The JUVENTAS study included 160 patients with no option
severe limb ischemia. The baseline characteristics have been
described previously and were not different between the
treatment groups.7 The mean increase in PCS at 6 months
compared with baseline was 6.3 (95% CI 4.1e8.4) in the
BMMNC group and 6.4 (95% CI 3.9e6.8) in the placebo
group. For MCS the mean increase was 3.9 (95% CI 0.0e7.8)
and 1.7 (95% CI 2.6e5.9), respectively. Follow up of
responding patients varied between 13 and 80 months
since inclusion. The median follow up was 35.7 months
(interquartile range (IQR) 21.4e50.9 months) and 32.9
months (IQR 21.2e50.6) for the BMMNC and placebo
groups, respectively. When the long-term follow up QoL
questionnaires were distributed, 126 patients (78.8%) were
still alive, and 34 had died (21.2%). Of the 126 patients
alive, 109 (86.5%) responded to the questionnaires and
were analyzed in this study (55 in BMMNC group, 54 in
placebo group), the baseline characteristics of the
responding patients are summarized in Table 1.
Mortality and amputation
Sixteen of 79 patients (20.3%) and 18 of 81 patients (22.2%)
in the placebo and BMMNC group had died by the start of
this follow up study (p ¼ .67).
Since randomization, 20 out of 79 patients (25.3%) in the
placebo group and 21 out of 81 patients (25.9%) in the
BMMNC group (p ¼ .93) had suffered a major amputation.
Overall the major amputation rates, either before or after
randomization, were 31.6% (25 of 79 patients) and 29.6%
(24 of 81 patients), respectively (p ¼ .87).
Of the 109 patients responding to the questionnaire, 19
suffered a major amputation since randomization and 27 had
suffered anymajor amputation before or after randomization.
Missing items in QoL questionnaires
In total, 17 patients (placebo 9, BMMNC 8) were contacted
but did not return the QoL forms. Seven of them had suf-
fered an amputation during the initial 6 month follow up
and 10 of them had suffered an amputation at long-term
follow up. The percentage of patients with an amputation
since randomization was higher in this non-responding
group, than in the group that did respond (p ¼ .001).
Three of the non-responders were lost to follow up
because of relocation and unknown address, one did not
respond because of severe dementia, and one patient
refused to complete the questionnaire because of a major
Figure 2. Norm based scores of all domains of Short Form-36
questionnaire. BP ¼ bodily pain; GH ¼ general health;
MCS ¼ mental component summary; MH ¼ mental health;
PCS ¼ physical component summary; PF ¼ physical functioning;
RE ¼ role-emotional; RP ¼ role-physical; SF ¼ social functioning;
VT ¼ vitality.
Table 1. Baseline characteristics of responding patients.
BMMNC (n ¼ 55) Placebo (n ¼ 54) P
Male sex 69.1% 53.7% .099
Age in years 67 (56e77) 67 (56e74) .411
Amputation after inclusion 9.1% 9.3% .976
Obesity 14.5% 20.4% .423
History of CVA 5.5% 5.6% .982
History of DM NIDDM 20.0% 13.0% 0.125
IDDM 12.7% 27.8%
Smoking Current 25.5% 34.0% 0.434
Never 16.4% 9.4%
Previous 58.2% 56.6%
Fontaine classiﬁcation Fontaine 2b 7.3% 7.4% 0.764
Fontaine 3 40.0% 33.3%
Fontaine 4 52.7% 59.3%
Note. Age is shown as median and interquartile range. BMMNC ¼ bone marrow derived mononuclear cell; CVA ¼ cerebrovascular
accident; DM ¼ diabetes mellitus; IDDM ¼ insulin dependent diabetes mellitus; NIDDM ¼ non-insulin dependent diabetes mellitus.
86 S.M.O. Peeters Weem et al.amputation. The remaining 12 patients did not respond for
unknown reasons.
Forty-nine patients (45%) had one or more missing items
in their returned questionnaires (23 patients in placeboTable 2. Scores in each domain of SF-36, median (interquartile range)
Domain SF-36 BMMNC group (n ¼ 55)
Physical functioning 45.00 (25.00e60.00)
Role physical 25.00 (0.00e50.00)
Role emotional 66.67 (33.33e100.00)
Vitality 55.00 (40.00e65.00)
Mental health 72.00 (56.00e88.00)
Social functioning 62.50 (50.00e87.50)
Bodily pain 45.00 (35.00e67.50)
General health 45.00 (30.00e65.00)
PCS 33.93 (28.66e42.97)
MCS 52.37 (43.54e58.62)
BMMNC ¼ bone marrow derived mononuclear cells; MCS ¼ mental cgroup, 26 in BMMNC group). The groups of patients with
and without missing data showed no signiﬁcant differences
in treatment group, age, gender, BMI, history of major
amputation, Fontaine’s classiﬁcation at baseline and at 6
months, and pain free walking distance at baseline and at 6
months. Therefore data were imputed without correction
for these factors.QoL in no option severe limb ischemia patients
Participating no option severe limb ischemia patients
demonstrated low scores on every domain of the SF-36.
Median NBS were below the general population mean of
50. Low scores were, in particular, observed in the physical
domains of the SF-36, as illustrated in Fig. 2.BMMNC versus placebo
The QoL scores did not differ between the BMMNC and
placebo group at long-term follow up in any of the SF-36
domains, as displayed in Table 2.
The QoL scores of the EQ5D questionnaire did not differ
signiﬁcantly between the groups, the mean tariff score for
the placebo group was 0.63 (SD 0.26) and for the BMMNC
group 0.65 (SD 0.23) (p ¼ .30). The median EQ-VAS score
was also similar in the placebo (63.50; IQR 55.00e74.00)
and BMMNC group (61.00; IQR 57.00e75.00, p ¼ .82).by treatment group.
Placebo group (n ¼ 54) P
40.00 (15.00e60.00) .359
25.00 (0.00e75.00) .588
66.67 (33.33e100.00) .256
45.00 (35.00e65.00) .308
72.00 (60.00e84.00) .808
62.50 (37.50e87.50) .878
55.00 (45.00e77.50) .441
45.00 (30.00e55.00) .483
34.27 (29.37e42.10) .788
47.77 (40.82e55.11) .258
omponent summary; PCS ¼ physical component summary.
Table 3. Mean changes in physical and mental component summary.
Dimension BMMNC 95% CI Placebo 95% CI N
Inclusion e long-term DPCS 4.38 (1.77e6.98) 4.19 (1.22e7.16) 50/50
DMCS 4.10 (0.24e7.97) 2.54 (1.00e6.10) 50/50
6 months e long-term DPCS 1.61 (4.49e1.27) 2.08 (4.68e0.52) 37/43
DMCS 2.43 (5.92e1.05) 0.71 (3.18e4.59) 37/43
CI ¼ conﬁdence interval; MCS ¼ mental component summary; PCS ¼ physical component summary.
Table 4. Scores in each domain of SF-36, median [interquartile range] by history of amputation.
Domain SF-36 No amputation (n ¼ 89) Amputation (n ¼ 20) P
Physical functioning 45.00 (25.00e60.00) 25.00 (15.00e50.00) .016
Role physical 25.00 (0.00e50.00) 25.00 (0.00e100.00) .157
Role emotional 66.67 (33.33e100.00) 66.67 (33.33e100.00) .796
Vitality 50.00 (40.00e60.00) 55.00 (35.00e65.00) .585
Mental health 72.00 (52.00e84.00) 80.00 (64.00e88.00) .113
Social functioning 62.50 (50.00e87.50) 62.50 (37.50e87.50) .503
Bodily pain 45.00 (35.00e67.50) 75.00 (45.00e90.00) .016
General health 45.00 (30.00e55.00) 50.00 (40.00e70.00) .113
PCS 33.08 (28.51e42.61) 36.66 (32.09e43.92) .215
MCS 50.25 (39.41e56.22) 49.95 (43.52e58.62) .459
MCS ¼ mental component summary; PCS ¼ physical component summary.
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The mean increases in PCS and MCS compared to baseline
were 4.38 (95% CI 1.77e6.98) for the BMMNC and 4.19
(95% CI 1.22e7.16) for the placebo group and 4.10 (95%
CI 0.24e7.97) for the BMMNC and 2.54 (95% CI e1.00 to
6.10) for the placebo group, respectively. The PCS and
MCS at long-term were not signiﬁcantly different from 6
months, in both trial arms. Overall, the increase in QoL
observed at 6 month follow up is maintained at the long-
term follow up. The mean changes in PCS and MCS are
displayed in Table 3.Patients with and without major amputation
For the 19 responding patients that had an amputation
since inclusion, median time between amputation and
completion of the questionnaire was 25 months (IQR 20e
43 months). For the 27 responding patients that had a
contralateral amputation before or ipsilateral amputation
after inclusion, median time between amputation and
completion of the questionnaire was 30 months (IQR 20e
54 months). Three of these 27 patients had suffered a
bilateral amputation.
When SF-36 scores of patients with and without ampu-
tation were compared, there were only statisticallyTable 5. Factors contributing to physical component summary (PCS) a
PCS
b 95% CI
Age categorya 0.129 1.412 to 1.669
Female sex 2.522 6.653 to 1.609
History of CVA 0.313 9.583 to 8.957
History of DM 2.799 0.129 to 5.726
Obesity 5.414 11.089 to 0.260
Smoking status 2.322 1.081 to 5.725
CI ¼ conﬁdence interval.
a Per 10 years older.signiﬁcant differences in the domains ‘physical functioning’
in favor of patients without a history of amputation (45.00
[IQR 25.00e60.00] vs. 25.00 [IQR 15.00e50.00], p ¼ .02),
and in ‘bodily pain’ in favor of patients with a history of
amputation (45.00 [IQR 35.00e67.50] vs. 75.00 [IQR
45.00e90.00], p ¼ .02; see Table 4). However, these dif-
ferences were not statistically signiﬁcant after correction for
multiple testing. The EQ5D mean tariff score was not
signiﬁcantly different in patients with and without a major
amputation (0.68 [SD 0.23] vs. 0.63 [SD 0.25] respectively,
p ¼ .30).
The increase in score for patients after amputation
compared to baseline (before amputation) was signiﬁcant
for MCS (p ¼ .04) and showed a trend for PCS (p ¼ .07). The
group of patients with a bilateral amputation was too small
to detect differences in QoL between unilateral and bilateral
amputees.Predictors of quality of life
Age, sex, history of cerebrovascular accident (CVA), history
of diabetes, obesity, and smoking status did not signiﬁcantly
relate to QoL scores in patients with no option severe limb
ischemia, measured by the PCS and MCS. The results are
summarized in Table 5.nd mental component summary (MCS).
MCS
p b 95% CI P
.869 0.387 2.167 to 1.393 .667
.228 0.992 3.780 to 5.764 .681
.947 2.326 13.035 to 8.382 .667
.061 1.424 4.806 to 1.958 .405
.061 2.243 8.799 to 4.312 .498
.179 2.834 6.766 to 1.089 .156
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naire, the only signiﬁcantly contributing factor was age
(b ¼ 3.41, 95% CI 0.40e6.43). In this population, higher age
seems to contribute to a higher SF-36 general health score.
For the domain “bodily pain” the only contributing factor
was the presence of diabetes mellitus (b ¼ 7.09, 95% CI
0.39e13.79), which seems to increase the score for this
domain. For the remaining six domains of the SF-36 there
were no signiﬁcantly contributing characteristics identiﬁed.DISCUSSION
The present extended analysis of the JUVENTAS trial
investigated the long-term QoL of patients with no option
severe limb ischemia. The results of this study showed that
the increase in QoL observed in the JUVENTAS study at 6
months’ follow up persisted at a median of 35 months’
follow up. There were no signiﬁcant differences between
the BMMNC and placebo group or between patients with
and without a history of a major amputation.
It was hypothesized that the equally improved QoL in the
BMMNC and placebo group of the JUVENTAS trial might be
related to the effect of trial participation itself. The positive
effect of trial participation is previously described as the
“Hawthorne effect”. Originally, the observed effect was that
productivity of workers at the Western Electrical company
increased no matter what change in working conditions was
introduced and the hypothesis was that this increase in
worker productivity was produced by the psychological
stimulus of being singled out and made to feel important.
This effect has been extrapolated to trial patients and is
thought to account for the positive effects of trial
participation.11,12
It was previously reported that patients who assumed
they took an active drug had higher QoL scores than pa-
tients who assumed they took placebo.11,13,14 The fact that
the increases in QoL compared with baseline remained
signiﬁcant at long-term follow up in most domains of the
SF-36 reduces the likelihood that the Hawthorne effect
played an important role, since at long-term follow up there
were no additional visits or care for participating patients,
so that beneﬁt from extra attention is not expected. How-
ever, a potential long-term “placebo-effect” cannot be ruled
out, since patients were still blinded to treatment allocation
at the time that questionnaires for the current study were
completed. Investigation of the QoL after unblinding of the
participants could be an interesting addition to this analysis.
Another possible explanation for the increased long-term
QoL is the effect previously referred to as “learning ef-
fect”, which means that completing a questionnaire repet-
itively modiﬁes the results because the subject learns how
to ﬁll it out.15 Furthermore, the factor “time” seems to be
an important variable; QoL scores may differ over time
because of spontaneous evolution or because another
aspect related to time, like the season, has changed.15
The number of patients, especially those in the subgroup
with major amputation, was too small to draw deﬁnite
conclusions; however, QoL in patients with or without ahistory of major amputation did not differ substantially.
Whereas patients without a major amputation score higher
in the domain “physical functioning”, patients with a history
of major amputation have a higher QoL score in the domain
“bodily pain”. In the remainder of the domains and in the
summary scores, both groups have similar results. Notably,
the non-responders had higher amputation rates than the
responding patients. QoL in responding patients with an
amputation did not differ signiﬁcantly from responding
patients that did not suffer an amputation. However, it is
possible that the non-responding amputees are speciﬁcally
those patients with worse QoL, which might lead to over-
estimation of the QoL in the group of amputees. Other
potential reasons for not responding to the questionnaires
might also be related to a worse QoL, and hence result in
further overestimation of the actual QoL. Furthermore,
approximately 45% of the returned questionnaires had one
or more missing items, which were imputed and hence
might have inﬂuenced the results.
The reliability of the summary scores (PCS and MCS) has
been subject of debate, mainly because of different results
from correlated and uncorrelated component summary
scores.16e19 This could lead to misinterpretation of the re-
sults of the SF-36 questionnaires. However, the scores of
the eight domains were also analyzed separately, and pro-
vided similar results.20 In conclusion, the improved QoL in
no option severe limb ischemia patients that participated in
the JUVENTAS trial persisted after ﬁnishing the study until a
median follow up of 35 months, without any difference
between the BMMNC and placebo treated patients.
Moreover, the occurrence of a major amputation did not
substantially inﬂuence QoL.
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